Evidence map›Paper›PMID 38280289›Full record

ArticleOral oncology2024

Complete tumor resection reverses neutrophilia-associated suppression of systemic anti-tumor immunity.

Amir Kaskas, Paul Clavijo, Jay Friedman, Marco Craveiro, Clint T Allen

Open access · greenAbstract read
In one paragraph

Article in Oral oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Amir KaskasSurgical Oncology Program, Center For Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Paul ClavijoSurgical Oncology Program, Center For Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jay FriedmanSurgical Oncology Program, Center For Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Marco CraveiroSurgical Oncology Program, Center For Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Clint T AllenSurgical Oncology Program, Center For Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: clint.allen@nih.gov.
National Institutes of Health · USNational Cancer Institute · US

Funding

Enhancing anti-tumor immunity in head and neck neoplasmsZIABC012131 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALLEN, CLINT · 2023 to 2025
$13.4M
Intramural NIH HHS ZIA BC012131
6 · The paper itself

Abstract

objectivesTumor infiltrating neutrophils suppress T cell function, but whether neutrophils in circulation contribute to systemic immunosuppression is unclear. We aimed to study whether peripheral neutrophils that accumulate with tumor progression contribute to systemic immunosuppression, and if observed suppression of systemic anti-tumor immunity could be reversed with complete surgical tumor removal. MATERIALS AND

methodsSyngeneic murine oral cancers were established in immunocompetent mice. Proteomic and functional immune assays were used to study plasma cytokine concentration, peripheral immune frequencies, and systemic anti-tumor immunity with and without complete primary tumor resection.

resultsLy6G

conclusionsComplete primary tumor resection can reverse neutrophilia that develops during tumor progression and result in enhanced systemic anti-tumor immunity. Primary tumor removal relieves neutrophil-driven systemic immunosuppression and may itself contribute to the clinical benefit observed with neoadjuvant immunotherapy.

Indexed as

Immunosuppression TherapyProteomicsAnimalsCell Line, TumorImmune ToleranceImmunotherapyMiceTumor MicroenvironmentImmunosuppressionNeoadjuvant immunotherapyNeutrophilsSystemic anti-tumor immunityTumor resection

Identifiers

PMID38280289
PMCPMC10939739
OpenAlexW4391255781

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.